20260615_PYFA_Ringkasan Risalah//Risalah RUPS_32101201_lamp1.pdf

   Director                : ANTES EKO PRASETIO
   Director                : SINTA LESTARI NINGSIH

   Board of Commissioners:
   President Commissioner           : ROBBY YULIANTO
   Commissioner                     : dr. WIDJANARKO BROTOSAPUTRO
   Independent Commissioner         : MAURA LINDA SITANGGANG
   Independent Commissioner         : CHARLES D. MARPAUNG

C. The Meeting was attended by 7,596,529,353 shares carrying valid voting rights, representing
   67.60% of the total issued shares of the Company with valid voting rights.

D. During the Meeting, each shareholder or their proxy was given the opportunity to raise
   questions and/or express opinions regarding each item on the Meeting agenda.

E. The voting procedures at the Meeting were as follows:
   Meeting resolutions were adopted through deliberation to reach a consensus. If any
   shareholder or proxy voted against a proposal or abstained from voting, the resolution was
   put to a vote.

F. The number of shareholders/proxies who raised questions and/or expressed opinions, as well
   as the voting results for each agenda item of the Annual General Meeting of Shareholders,
   were as follows:

                     Number of                           Voting Results
                    Shareholders/
       Agenda
                       Proxies
       AGMS                               Agree               Against        Abstain/Blank
                       Raising
                      Questions
                                       7.593.249.652                            2.749.700
                                                          530.001 shares
                                           shares                                 shares
          1                2                                (0,0070% of
                                       (99,9568% of                            (0,0362% of
                                                          shares present)
                                      shares present)                        shares present)
                                       7.593.779.652                            2.749.700
                                           shares          1 share (0% of         shares
          2                0
                                       (99,9638% of       shares present)      (0,0362% of
                                      shares present)                        shares present)
                                       7.593.779.652                            2.749.700
                                           shares          1 share (0% of    shares (0,0362
          3                0
                                       (99,9638% of       shares present)        of shares
                                      shares present)                            present)
                                       7.593.779.652                            2.749.700
                                           shares          1 share (0% of         shares
          4                0
                                       (99,9638% of       shares present)      (0,0362% of
                                      shares present)                        shares present)
                                       7.593.779.652       1 share (0% of       2.749.700
          5                0
                                           shares         shares present)         shares

                                         (99,9638% of                               (0,0362% of
                                        shares present)                           shares present)
                                         7.593.779.652                               2.749.700
                                             shares           1 share (0% of           shares
           6                0
                                         (99,9638% of        shares present)        (0,0362% of
                                        shares present)                           shares present)
                                         7.593.779.652                               2.749.700
                                             shares           1 share (0% of           shares
           7                0
                                         (99,9638% of        shares present)        (0,0362% of
                                        shares present)                           shares present)

G. At the Meeting, the following resolutions were duly adopted by majority vote:
   I.      First Agenda
           1. To approve the Company's Annual Report and Sustainability Report and to ratify
                the Company's Financial Statements for the financial year ended December 31,
                2025.
           2. Following the approval of the Company's Annual Report, including the
                Sustainability Report and the Supervisory Report of the Board of Commissioners
                for the financial year ended December 31, 2025, as well as the ratification of the
                Company's Consolidated Financial Statements for the financial year ended
                December 31, 2025, which were audited by Purwanto, Susanti and Surja Public
                Accounting Firm, a member firm of Ernst & Young, and which, in all material
                respects, fairly present the financial position of the Company, the Meeting
                granted a full release and discharge (volledig acquit et de charge) to all members
                of the Board of Directors and the Board of Commissioners for their management
                and supervisory actions carried out during the financial year ended December 31,
                2025, insofar as such actions do not constitute criminal acts and are reflected in
                the Company's Annual Report, Sustainability Report, and Consolidated Financial
                Statements for the financial year ended December 31, 2025.
           3. To grant authority, with the right of substitution, to the Board of Directors of the
                Company, acting jointly or individually, to take all actions necessary in connection
                with the foregoing resolutions, including but not limited to preparing, signing, and
                submitting all required documents, stating such resolutions in a separate notarial
                deed, and subsequently notifying the relevant authorities of the Company's
                Annual Report in accordance with the applicable laws and regulations.

    II.     Second Agenda
            To approve the recording of a net loss of IDR 379,670,109,302 (three hundred
            seventy-nine billion six hundred seventy million one hundred nine thousand three
            hundred two Rupiah) for the 2025 financial year, and not to allocate any profit to
            statutory reserves or distribute any dividends in respect of the 2025 financial year.

III.   Third Agenda
       To grant authority and power to the Board of Commissioners of the Company to
       determine the amount of salaries or honoraria and other allowances for the members
       of the Board of Commissioners and the Board of Directors of the Company for the
       financial year ending December 31, 2026, based on a resolution of the Board of
       Commissioners, including the aggregate amount of salaries, honoraria, tantiem, and
       other benefits for the Board of Directors and the Board of Commissioners, while
       taking into account the Company's financial condition and performance.

IV.    Fourth Agenda
       To grant authority to the Board of Commissioners to appoint the Public Accounting
       Firm that will audit the Company's Financial Statements for the financial year ending
       December 31, 2026, taking into consideration the proposal of the Board of
       Commissioners and the recommendation of the Company's Audit Committee, and to
       authorize the Board of Directors to determine the fees of such public accountant and
       other related terms and conditions, considering that the Company still requires time
       to monitor and evaluate performance and to assess prospective public accountants
       to be appointed based on input from the Board of Commissioners and the Audit
       Committee, as well as other objective considerations deemed necessary in making
       such decision.

V.     Fifth Agenda
       Approve the Public Offering Report of Continuous Bonds I Pyridam Farma Phase III
       Year 2024 as of 31 December 2025 in the amount of Rp321,594,822,184 (three
       hundred twenty-one billion five hundred ninety-four million eight hundred twenty-
       two thousand one hundred eighty-four rupiah), as referred to in the Report on the
       Realization of the Use of Funds from the Continuous Bond Public Offering I Pyridam
       Farma Phase III Year 2024, with letter number: 009/PYFA-CS/I/2026 dated 15 January
       2026, the Public Offering Report of Continuous Bonds II Pyridam Farma Phase I Year
       2025 as of 31 December 2025 in the amount of Rp400,000,000,000 (four hundred
       billion rupiah), as referred to in the Report on the Realization of the Use of Funds from
       the Continuous Bond Public Offering II Pyridam Farma Phase I Year 2025, with letter
       number: 011/PYFA-CS/I/2026 dated 15 January 2026 and letter number: 011a/PYFA-
       CS/II/2026 dated 4 February 2026, and the Limited Public Offering Report to
       Shareholders through Capital Increase by Granting Pre-emptive Rights I and Issuance
       of Series I Warrants, whereby the Company has completed the realization of the use
       of all proceeds from the conversion of Series I Warrants into shares as of 31 December
       2025 in the amount of Rp10,235,200 (ten million two hundred thirty-five thousand
       two hundred rupiah), as referred to in the Report on the Realization of the Use of
       Funds from the Limited Public Offering to Shareholders through Issuance of Series I
       Warrants, with number: 010/PYFA-CS/I/2026 dated 15 January 2026.

VI.    Sixth Agenda
       1. To approve the amendment to the Company’s Articles of Association, namely the
          adjustment of the wording related to the Company’s business activities as
          stipulated in Article 3 of the Company’s Articles of Association concerning the
          Company’s Purpose and Objectives and Business Activities, to align with Statistics

  Indonesia (Badan Pusat Statistik) Regulation No. 7 of 2025 on the Standard
  Classification of Indonesian Business Fields (KBLI 2025), as follows:

              OBJECTIVES AND PURPOSES AND BUSINESS ACTIVITIES
                                 ARTICLE 3

The objectives and purposes of the Company, as well as its business activities in
accordance with Statistics Indonesia Regulation No. 7 of 2025 concerning the
Indonesian Standard Classification of Business Fields (KBLI 2025) (hereinafter referred
to as the “KBLI”), are as follows:

1. The Company’s Main Business Activities are as follows:
   A. CLEANING MATERIALS AND PRODUCTS INDUSTRY
   To carry out business activities in the manufacture of cream soap, dishwashing
   soap; detergents and other household cleaning agents; paper, cotton wool,
   textiles, and the like coated with soap or detergent, such as wet wipes; crude
   glycerol; surfactant preparations such as washing powder, both solid and liquid,
   dishwashing detergents, and fabric softeners; cleaning and polishing products
   such as air fresheners and room deodorizers, artificial wax and processed wax,
   polish and creams for leather goods, wood polish and creams, glass and metal
   polish, and scouring pastes and powders, including paper, pads, and others
   coated with polishing pastes and powders; antiseptic and household disinfectant
   products.

    B. HUMAN COSMETICS INDUSTRY, CONTACT LENS SOLUTIONS
    To carry out business activities in the manufacture of human cosmetics, such as
    hair care products (shampoo, hair curling and straightening products, etc.); nail
    care products (manicure and pedicure); skin care products (sunscreen creams or
    lotions and tanning products); personal hygiene products (cosmetic soap, bath
    soap, antiseptic bath soap, external intimate hygiene products, deodorants, bath
    salts, etc.); shaving products; decorative cosmetics such as facial makeup, eye
    makeup, perfumes, nail makeup, and hair makeup, including hair dye; toothpaste
    and oral hygiene products, including cosmetic teeth whitening products; and
    contact lens solutions.

    C. HUMAN PHARMACEUTICAL RAW MATERIALS INDUSTRY
    To carry out business activities in the manufacture and processing of
    pharmaceutical raw materials and supporting materials for human use derived
    from chemicals, natural resources, animals, and plants, including biological
    products such as medicinal substances, including antisera and other blood
    fractions, vaccines, and homeopathic preparations, active pharmaceutical
    substances (antibiotics, vitamins, salicylic acid, acetylsalicylic acid, etc.) for
    pharmaceutical use, blood processing, chemically pure sugar, pharmaceutical-
    grade salts, gland processing, and gland extraction.

D. HUMAN PHARMACEUTICAL PRODUCTS INDUSTRY
To carry out business activities in the manufacture and processing of finished
pharmaceutical products, health supplements/food supplements, and quasi
drugs for human use in the form of tablets, capsules, ointments, powders,
solutions, parenteral solutions, suspensions, hormonal contraceptives;
production of radiopharmaceuticals; and pharmaceutical biotechnology
products.

E. INDUSTRY OF MEDICAL DIAGNOSTIC DEVICES, BANDAGES, GAUZE, AND
OTHER HEALTH SUPPORT PRODUCTS
To carry out business activities in the manufacture and processing of medical
devices for diagnostic purposes and other products under subclass 2011. This
includes external contraceptive products; medical diagnostic devices such as
pregnancy test kits and blood glucose test kits; medical cotton, cosmetic cotton,
cotton buds, bandages, medical gauze, plasters; nasal wash products, and
personal lubricants.

F. TRADITIONAL MEDICINE PRODUCTS INDUSTRY FOR HUMAN USE
To carry out business activities in processing various traditional medicine
products derived from natural resources in raw or minimally processed form from
plants, animals, microorganisms, minerals, or their combinations, in forms such
as powders, instant powders, slices, pills, dodol/gel-like preparations, pills,
pastes, tablets, capsules, liquids, solutions, emulsions, suspensions, effervescent
forms, films, strips, gummy chewables, ointments, lotions, creams, gels, aerosol
external medicines, patches, and suppositories; including herbal beverages and
health supplements that are not classified as pharmaceutical products.

G. GLASS LABORATORY AND HEALTH EQUIPMENT INDUSTRY
To carry out business activities in the manufacture of various laboratory and
medical equipment made of glass, including clinical laboratory tools for
diagnostic purposes such as test tubes for biological samples (blood, urine,
saliva), as well as non-clinical laboratory and health equipment such as serum
bottles/infusion bottles, ampoules, test tubes, measuring tubes, microscope
slides, cuvettes, and desiccators.

H. OTHER PLASTIC PRODUCTS INDUSTRY
To carry out business activities in the manufacture of plastic goods not classified
under subclass 2220, such as
- office/educational equipment; plastic medical/laboratory equipment such as
    infusion bags and tubing;
- cellophane films or sheets;
- synthetic stone made of plastic; plastic signage (non-electrical);
- various plastic goods such as headgear, sealing equipment, lighting
    components, clothing items (if only sealed or assembled, not sewn), furniture
    accessories, sculptures, plastic adhesive tapes, plastic wall coverings, durable
    plastic shoes, cigar and cigarette holders, combs, hair curlers, and other
    plastic items.

This group also includes processing and finishing activities of plastic goods such
as metal coating or other surface treatment and painting (excluding plastic
automotive parts and accessories).

I. WHOLESALE TRADE OF MEDICAL AND LABORATORY EQUIPMENT FOR
HUMAN USE
To carry out business activities including wholesale trade of laboratory
equipment, medical, surgical, orthopedic devices, and similar equipment for
human use.

J. WHOLESALE TRADE OF PHARMACEUTICAL PRODUCTS FOR HUMAN USE
To carry out business activities in the wholesale distribution of pharmaceutical
preparations, including medicinal raw materials, natural medicinal substances,
cosmetics, quasi drugs, health supplements, medicines, and traditional medicines
intended for human use.

N. TECHNICAL TESTING SERVICES
To carry out business activities including:
    - sampling activities to determine material or process characteristics;
    - calibration/metrology activities in measurements of temperature, mass,
        volume, pressure, force, torque, flow, hardness, density, length,
        electricity, magnetism, time, frequency, acoustics, vibration,
        photometry, radiometry, and ionizing radiation analytical instruments;
        testing covering physical, mechanical, chemical, biological,
        microbiological,      electrical,   nuclear,  visual/checklist,       design
        model/prototype, forensic or other analyses across various
        materials/products in industries such as manufacturing, trade, energy,
        construction, transportation, telecommunications, pharmaceuticals,
        food, agriculture, forestry, and environmental quality (water, air, soil,
        and other indicators);
    - periodic conformity assessment of laboratory physical characteristics,
        composition, and performance;
    - periodic testing or calibration of medical equipment;
    - quarantine testing of animals, plants, and fisheries;
    - marine testing;
    - testing of machinery and ionizing radiation equipment such as survey
        meters, contamination meters, dosimeters, and X-ray multimeters;
    - calibration activities for industrial instruments such as machines,
        equipment, and measuring tools;
    - electronics and other technology testing.
This group also includes calibration/metrology and certification activities to verify
and validate measuring instruments or calibration tools to ensure their accuracy
and reliability.

       2. Supporting Business Activities Of The Company are:
          A. HOLDING COMPANY ACTIVITIES
          To carry out activities of holding companies, such as units that hold assets (owning
          and managing equity interests) in one or more subsidiaries and are only
          responsible as the owner of such subsidiaries. Companies in this group do not
          provide other services to companies whose equity is held by the holding company;
          for example, the holding company does not manage or operate other units.Such
          holding companies may conduct activities such as control, financial consolidation,
          and being responsible for the activities of each subsidiary, but not the active
          management of those subsidiaries, for example, financial conglomerate holding
          companies.

         B. OTHER MANAGEMENT AND BUSINESS CONSULTING ACTIVITIES
         To carry out activities including advisory, guidance, and operational assistance in
         business and other organizational and management matters, such as strategic and
         organizational planning; financial decision-making; planning objectives and
         policies; human resource planning, practices, and policies; production scheduling
         and control planning. The provision of these services may include advisory
         assistance and operational support across various management functions,
         agronomist and agricultural economist consulting in agriculture and related fields,
         design of accounting methods and procedures, cost accounting programs, budget
         control procedures, provision of advice and assistance to businesses and public
         services in planning, organization, efficiency, and supervision, management
         information services, occupational health and safety consulting such as risk
         identification and documentation, and others.

       2. To grant authority, with substitution rights, to the Board of Directors of the
          Company, jointly or individually, to take all actions in connection with the above
          resolutions, including but not limited to preparing, signing, and submitting all
          required documents, stating them in a separate notarial deed before a Notary, and
          subsequently applying for approval of amendments to the Company’s Articles of
          Association to the competent authorities in accordance with applicable laws and
          regulations.

VII.   Seventh Agenda
       1. To accept the resignation of Mr. Robby Yulianto as President Commissioner of the
          Company, with appreciation for his services and performance in carrying out the
          supervisory duties of the Company.
       2. To appoint Mr. Widjanarko Brotosaputro as President Commissioner of the
          Company, effective as of the closing of this Meeting and until the end of his term
          of office, continuing the remaining term of the replaced member of the Board of
          Commissioners in accordance with Article 32 paragraph (5) of the Company’s
          Articles of Association, without prejudice to the right of the General Meeting of
          Shareholders to dismiss him at any time.
       3. To determine the composition of the Company’s Board of Commissioners,
          effective as of the closing of this Meeting until the end of the respective terms of
          office at the Annual General Meeting of Shareholders to be held in 2030, without

    prejudice to the right of the General Meeting of Shareholders to dismiss them at
    any time, as follows:
    1. Mr. dr. WIDJANARKO BROTOSAPUTRO as President Commissioner;
    2. Mr.CHARLES D. MARPAUNG as Independent Commissioner; and
    4. Mrs. MAURA LINDA SITANGGANG as Independent Commissioner.

4. To grant authority, with substitution rights, to the Board of Directors of the
   Company, jointly or individually, to take all necessary actions in connection with
   the above resolutions, including but not limited to preparing, signing, and
   submitting all required documents, stating such resolutions in a separate notarial
   deed before a Notary, and subsequently notifying the changes in the Company’s
   management structure to the relevant authorities in accordance with applicable
   laws and regulations.



                       Jakarta, June 15, 2026

                        Board of Directors
                      PT Pyridam Farma Tbk.